
Opinion|Videos|December 11, 2024
Introduction to the Discussion of Frontline Treatment for Newly Diagnosed Lower-Risk Myelodysplastic Syndromes.
Author(s)Guillermo Garcia-Manero, MD, David Swoboda, MD
Following a recent update in to NCCN gGuidelines, Drs. Garcia- Manero and Swoboda introduce themselves and theirwill discussion about the changing landscape of lower-risk myelodysplastic syndromeLR-MDS treatment.
Advertisement
Episodes in this series

Now Playing
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Accepts BLA for Ivonescimab in Pretreated EGFR-Mutated NSCLC
2
The Targeted Pulse: New Standards in Myeloma, Melanoma, and More
3
Onvansertib Triplet Shows Dose-Dependent Frontline Benefit in RAS-Mutant Metastatic CRC
4
Pembrolizumab/Lenvatinib Show Efficacy, Safety in Clear Cell Gyn Cancers
5



















